{"id":"azd6234-in-combination-with-azd9550","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD6234 works by inhibiting the PI3K pathway, which is involved in cell growth and survival. AZD9550 targets CDK9, an enzyme that plays a role in the transcription of genes involved in cancer cell proliferation. By combining these two mechanisms, AZD6234 and AZD9550 aim to inhibit cancer cell growth and survival.","oneSentence":"AZD6234 is a PI3K inhibitor, and AZD9550 is a CDK9 inhibitor, which together target cancer cell growth and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:52.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT06862791","phase":"PHASE2","title":"A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-18","conditions":"Obesity or Overweight","enrollment":377},{"nctId":"NCT07017179","phase":"PHASE2","title":"This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Obesity/Overweight","enrollment":871},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD6234 in combination with AZD9550","genericName":"AZD6234 in combination with AZD9550","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6234 is a PI3K inhibitor, and AZD9550 is a CDK9 inhibitor, which together target cancer cell growth and survival. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}